Introduction
============

Post-traumatic stress disorder (PTSD) is a chronic psychiatric condition that may develop after experiencing a potentially traumatic event. The disorder manifests itself at different levels, through symptoms such as sleep disturbances; changes in cognition (e.g., repeated recall of the event), mood (e.g., depression, anxiety), and emotion (e.g., psychological instability); and reduced social skills. Through the fourth edition of the DSM-IV, post-traumatic stress was classified as an anxiety disorder; however, the latest edition, DSM-V, includes PTSD in a new category called "trauma- and stress-related disorders.". In this brand-new category, we consider disorders with poor adaptation to a traumatic experience. Maladaptive responses to trauma may trigger, among others, PTSD ([@B79]; [@B4]).

At some point in their lives, approximately 10% of people will be affected by PTSD, resulting in an enormous economic and social impact. This impact is aggravated by the scarcity of psychological and, above all, pharmacological approaches to PTSD treatment ([@B45]; [@B104]; [@B52]). At present, approved treatments for PTSD involve anxiolytics and antidepressants, which are inefficient and have considerable side effects ([@B6]; [@B91]; [@B7]).

The eCB system can provide more efficient and better tolerated alternatives to the standard treatments for PTSD. The eCB system plays an important role in the regulation of emotional behavior and is essential for synaptic processes that determine learning and emotional responses, especially those related to potentially traumatic experiences ([@B22]; [@B85]). Among the possible alternative approaches, the use of components from *Cannabis sativa* such as CBD is particularly promising. Recent reviews have reported promising results of CBD treatment of several neuropsychiatric disorders, including PTSD ([@B70]; [@B51]; [@B79]). What began as a possibility discovered in a study of an animal model of aversive conditioning ([@B9]) gained strength through results obtained in humans ([@B28]) (see **Figure [1](#F1){ref-type="fig"}** for a brief history of CBD in PTSD). Because the compound has been proved to be well tolerated by humans, both in overall safety and possible side effects ([@B5]), CBD is now considered a new therapeutic possibility for treating PTSD.

![Brief history of advances in research on the use of CBD in PTSD.](fnins-12-00502-g001){#F1}

This paper reviews the therapeutic potential of CBD in the treatment of PTSD. It starts from the first evidence obtained in animal studies ("bench research") and proceeds to knowledge gathered in human trials ("confirmation in human trials").

Cannabinoids and Trauma-Related Disorder
========================================

*Cannabis sativa* contains over 100 compounds called phytocannabinoids. Two of them demonstrate considerable therapeutic potential: Δ9-tetrahydrocannabinol (Δ^9^-THC), considered the main component responsible for the psychoactive effects of the plant, and CBD, the main non-psychotomimetic constituent of *Cannabis* ([@B2]; [@B72]; [@B39]). CBD constitutes about 40% of the active substances of the plant ([@B27]). However, its pharmacological effects are different from, and often even opposite to, those of Δ9-THC, and are not related to the development of tolerance and withdrawal syndrome ([@B71]; [@B5]).

In this context, it is also important to highlight the eCB system, discovered in the 20th century and responsible for a revolution in the understanding of numerous neuropsychological functions related to the modulation of emotional responses ([@B63]). The eCB system comprises two different cannabinoid receptors, their endogenous ligands, and enzymes involved in the synthesis and degradation thereof ([@B33]). eCB signaling is distributed throughout the CNS and peripheral tissues, regulating presynaptic release of both excitatory and inhibitory neurotransmitters. Cannabinoid type 1 (CB1) receptors are expressed by peripheral and central neurons, particularly in the central regions known to play important roles in anxiety and aversive learning, such as the amygdala, hippocampus, and cerebral cortex ([@B25]). In contrast, CB2 receptors are expressed mostly in immune cells, while also being present in the brain ([@B100]).

The two major endogenous ligands for CB1 and CB2 receptors are AEA and 2-AG. These eCBs are synthesized on demand, mainly postsynaptically, and act as retrograde messengers regulating the presynaptic release of various neurotransmitters, as mentioned above. AEA acts as a partial agonist of both CB1 and CB2 receptors, with a higher affinity for the former. In the CNS, 2-AG is the most abundant eCB, and non-selectively activates CB1 and CB2 receptors. AEA, 2-AG, and Δ^9^-THC, have been shown to exert their effects mainly through activation of CB1 receptors ([@B33]; [@B22]). In the case of eCBs, the effects are rapidly terminated through carrier-mediated uptake followed by intracellular enzymatic degradation. AEA and 2-AG are metabolized by monoacylglycerol lipase and FAAH, respectively. The eCBs regulate neuronal activity and plasticity by depolarization-induced suppression of inhibition or excitation ([@B101]). Both phenomena are forms of short-term synaptic plasticity that contribute to the regulation of a number of physiological functions, including memory and emotion. Additionally, eCBs appear to modulate the memory process by changing synaptic plasticity and mediating more persistent forms of synaptic plasticity (e.g., LTP and depression) in several brain areas ([@B64]; [@B33]; [@B93]).

These findings have established the importance of the eCB system in a number of neurophysiological functions and led to an emerging interest in the eCB-mediated modulation of emotionality. The first study to address the role of the eCB system in fear memory, specifically in its extinction, was published at the beginning of the last decade by [@B67]. In this study, the authors showed that genetic deletion of the CB1 receptor or its pharmacological blockade strongly impaired extinction of auditory-conditioned fear and that eCBs were released in the BLA during extinction. This discovery revealed that the eCB system has a central function in the extinction of aversive memories and may therefore be a promising target for the treatment of disorders related to inappropriate retention of such memories (for details see [@B67]). Precisely what processes underlie this function of the eCB system is presently unclear, raising the question whether CBD exerts its effects through a different pathway(s). Previous reports on eCB system involvement in CBD-induced effects have been equivocal. Because the endogenous ligands (e.g., AEA) and Δ^9^-THC act directly on the CB1 receptor, it is possible that some of the effects of CBD are also mediated by this receptor, albeit indirectly. Indeed, CBD may exert its therapeutic effect on PTSD through inhibition of the uptake or enzymatic degradation of eCBs ([@B8]), as suggested by some recent studies ([@B9]; [@B34]; [@B36]; [@B97]). However, if this is the case, what is the advantage of using CBD over agents that act directly on the CB1 receptor? The answer is simple: fewer complications (specifically, anxiogenic side effects). Agents that target the eCB system directly, such as THC, CB1 agonists, and FAAH inhibitors, have a biphasic effect, in which low doses are anxiolytic, but higher doses can be anxiogenic, in both preclinical models and humans. In contrast, CBD, when administered in acute systemic doses in models of general anxiety, does not cause anxiety even at high doses. However, few studies have examined chronic dosing effects of CBD in models of generalized anxiety, and such studies are needed for the safe long-term use of CBD ([@B11]).

Trauma-related disorders may involve dysregulation of the learning process of aversive memories. This process is fundamental for the individual to survive, because through it we avoid potentially dangerous situations without having to respond in a way that damages mental health ([@B82]). Consistent with this concept, neural circuits that support fear conditioning are related to circuits that are affected in clinical conditions such as PTSD ([@B29]). That the available drugs (such as antidepressants and anxiolytics) do not specifically target the memory process may be one of the reasons that pharmacological treatment of PTSD is so difficult ([@B94]). Currently approved treatments for PTSD include SSRIs and serotonin/noradrenaline reuptake inhibitors, both with low efficacy ([@B7]). The response rate for SSRIs rarely exceeds 60%, of which less than 30% represents complete remission ([@B6]). Moreover, the available treatments have considerable side effects, which may limit tolerance or even decrease adherence to the treatment ([@B91]). In this regard, interventions that act on the eCB system have shown promise since they can affect both the emotional (e.g., relieve PTSD symptoms) and cognitive (e.g., increase the efficiency of psychological approaches) aspects of the disorder ([@B51]; [@B95]; [@B99]).

Two important observations led to the consideration of cannabinoids for the treatment of PTSD: (i) patients with PTSD appear to be more likely to smoke *Cannabis*; and (ii) patients with PTSD have increased levels of cannabinoid receptors and reduced peripheral levels of AEA, suggesting that the CB1 receptor upregulation may be a result of low receptor occupancy caused in turn by the deficiency of AEA ([@B44]; [@B46]; [@B75]; [@B76]; [@B61]). Consistent with these observations, studies have made use of treatment with cannabinoids in animal models of traumatic event exposure to reduce the appearance of PTSD-like behavioral responses. These studies have demonstrated great potential of cannabinoids in the mitigation of maladaptive responses to trauma (for a more detailed review, see [@B105]).

When administered after a traumatic situation, cannabinoids may interfere with the acquisition and consolidation of memories of the event, thus mitigating the risk of subsequent symptoms. However, intervention at this stage may be inadvisable because not all people exposed to a traumatic situation will later manifest PTSD. Alternatively, cannabinoids may reduce traumatic memory by affecting its retrieval or reconsolidation, or by stimulating the process of aversive memory extinction. The latter mechanism may hold the most therapeutic promise, especially when taking into account exposure-based psychotherapies, which extinction mechanisms are thought to be engaged (reviewed in [@B4]).

Additionally, studies have shown CBD, in its isolated form, to be a constituent of *Cannabis* with enormous therapeutic potential not only for trauma-related disorders, but also for various other psychiatric and neurological disorders ([@B19]). Among the advantages of CBD are its high efficacy, lack of psychotomimetic properties or anxiogenic effects caused by eCB transmission activation, inability to induce tolerance and dependence, and safety at high doses both in humans and in animals ([@B5]). However, an alternative view must also be considered, according to which the therapeutic effects of *Cannabis* result from the interaction of all the compounds present in the plant (particularly THC and CBD) rather than the isolated action of a single compound. Such interaction, called in the pharmacology the "entourage effect" ([@B3]), still needs to be better studied (for further discussion of the use of the term "entourage effect" on plants effect, see [@B87]). In this review, we will focus on CBD effects in isolation.

CBD and PTSD: "From Bench Research..."
======================================

The fear-conditioning paradigm has been widely used in animals to better understand the processes of acquisition, consolidation, retrieval, reconsolidation, and extinction of aversive memories ([@B55]; [@B66]). Parallels can be drawn between the expression of fear and anxiety in humans (e.g., those suffering from PTSD) to the expression of conditioned fear in animals ([@B14]). Many studies use variations of this model (e.g., contextual fear conditioning) to better understand the effects of CBD on behavioral responses related to the recall of traumatic events. Briefly, this model involves the pairing of a neutral stimulus (called CS) with an aversive US, usually a mild foot shock. After successive rounds of pairing (or, in some cases, a single pairing), the animal learns that the CS precedes the US, leading to a series of physiological (e.g., cardiovascular responses) and behavioral (e.g., freezing) responses (for a more complete description of the fear conditioning paradigm, see [@B74]; [@B65]; [@B30]).

Intervention in the processes of acquisition and consolidation of aversive memories is not promising, since this approach can only be effective when closely following the traumatic event, that is, when it is not yet possible to know if the event will result in a disorder. However, intervention in the processes of retrieval, reconsolidation, and, especially, extinction may be a more promising alternative. Briefly, when reactivated by re-exposure (retrieval), an aversive memory enters a transitional state, where the original memory trace can be reconsolidated or extinguished. This process may be influenced pharmacologically (e.g., by administration of CBD) in order to block reconsolidation or facilitate extinction. The process involves repeated exposure to the CS without the US, which will lead to the formation of a new, US-free memory trace that will override the old (CS + US) trace and, consequently, cause a decrease in the behavioral and physiological responses related to fear (reviewed in [@B4]).

Animal studies have shown that CBD can affect every stage of the process of aversive conditioning. In addition, exposure to traumatic stress is essential for the development of PTSD, and CBD is effective in reducing both the cardiovascular responses and anxiogenic effects caused by stress ([@B83], [@B84]; [@B42]; [@B16], [@B20]). For example, CBD lowered responses related to trauma when administered before the acquisition ([@B58]) or retrieval ([@B57]) of aversive memories. CBD also proved to be effective in reducing responses to aversive memories by blocking the process of reconsolidation ([@B96]). However, the most promising alternative, suggested by exposure-based psychotherapies, may be through enhancement of the extinction process by CBD ([@B9]; [@B34]). Before discussing the facilitating effects of CBD on the extinction of aversive memories, it is necessary to highlight the role of the eCB system in this process.

The process of extinguishing an aversive memory requires the participation of CB1 receptors, which was discovered in a classic study by [@B67]. The authors showed that blocking the action of CB1 receptors, either by pharmacological antagonism or genetic deletion, in previously conditioned mice resulted in strongly impaired short- and long-term extinction in fear-conditioning tests (the function of CB1 receptors in the process of extinction of aversive memories is detailed in [@B103]; [@B62]). This finding raised a new question: Would potentialization of the eCB system facilitate the extinction process? The answer was not surprising, and several studies were published showing that eCB system potentialization could in fact facilitate fear extinction in different behavioral tasks ([@B24]; [@B9], [@B10]; [@B31]; [@B77]; [@B1]; [@B60]). From the answer to the previous question, another arose in Takahashi's lab -- one that would raise CBD as a therapeutic possibility for the treatment of trauma-related disorders: Given that, according to [@B8], CBD acts through potentialization of the eCB system, could CBD alone also facilitate the extinction of aversive memories? The answer once again was affirmative, and since then studies have shown that CBD can facilitate the extinction of aversive memories not only in animals ([@B9]; [@B34]), but also in humans ([@B28]). However, it is important to note that some studies suggest that the reduced expression of fear caused by CBD may result mostly from blocked reconsolidation of an aversive memory than its increased extinction ([@B96], [@B97]; [@B40]). Regardless of which stage of aversive memory processing CBD affects, it appears that, at least in animals, this compound interferes with memory processing in a way that potentially mitigates damaging responses.

In addition to the possibility of CBD affecting different processes involved in aversive memory, animal studies also show favorable effects of this compound in the control of other frequent manifestations of PTSD symptomatology, such as sleep disorders. Studies in rats indicate that CBD may contribute to an increase in sleep duration and depth, and a decrease in anxiety responses induced by sleep disturbance ([@B73]; [@B49]; [@B23]). In the case of anxiety, another frequent manifestation of PTSD symptomatology, therapeutic potential of CBD has also been reported. However, a thorough review of CBD and anxiety lies beyond the scope of this paper. The interested reader may want to see recent reviews by [@B11] and [@B56]. Even when all evidence from animal studies suggests an enormous therapeutic potential of CBD CBD for treating PTSD symptoms (for a summary, see **Table [1](#T1){ref-type="table"}**), it will still be limited if the results are not replicated in humans. Research has also been moving in this direction, as we will see in the next section.

###### 

CBD and PTSD: "from bench research...".

  References in chronological order   Animal/test(s) used                 Effective dose/route of administration               Effect                                               Possible mechanisms of action
  ----------------------------------- ----------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------
  [@B9].                              Rats/Contextual fear conditioning   CBD 2 μg/μl i.c.v.                                   Facilitated extinction of contextual fear memory     Via CB~1~ receptors
  [@B57].                             Rats/Contextual fear conditioning   CBD 10 mg/kg i.p. and CBD 30 nmol into the PL PFC.   Decreased retrieval of contextual fear memory        Not shown, but highlights the involvement of the PL PFC
  [@B58].                             Rats/Contextual fear conditioning   CBD 1 mg/kg i.p.                                     Decreased acquisition of contextual fear memory      Not shown
  [@B96].                             Rats/Contextual fear conditioning   CBD 10 mg/kg i.p.                                    Blockade reconsolidation of contextual fear memory   Via CB~1~ receptors
  [@B34].                             Rats/Contextual fear conditioning   CBD 0.4 μg/side intra-IL cortex                      Facilitated extinction of contextual fear memory     Via CB~1~ receptors and highlights the involvement of the IL cortex
  [@B97].                             Rats/Contextual fear conditioning   CBD 1 mg/kg i.p. + THC 0.1 mg/kg i.p.                Blockade reconsolidation of contextual fear memory   Not shown
  [@B40].                             Rats/Contextual fear conditioning   CBD 10 mg/kg i.p.                                    Blockade reconsolidation of contextual fear memory   Not shown
                                                                                                                                                                                    

CBD, cannabidiol; i.c.v., intracerebroventricular; i.p., intraperitoneally; PL PFC, prelimbic prefrontal cortex; IL, infralimbic.

CBD and PTSD: "...To Confirmation in Human Trials"
==================================================

Confirming animal study results in humans is essential for the validation of any strategy that demands a pharmacological therapy. Some studies have shown that, in the case of CBD as a therapeutic alternative for PTSD, this translation is possible (for a summary, see **Table [2](#T2){ref-type="table"}**).

###### 

CBD and PTSD: "\...to confirmation in human trials."

  References in chronological order   Subjects/test(s) used                                 Effective dose/route of administration                            Effect                                                                                                        Possible mechanisms of action
  ----------------------------------- ----------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------
  [@B79].                             19 year-old male with PTSD (case report)              CBD + THC (cannabis resin from Turkey -- 1/1 proportion)/smoked   Patient experienced reduced stress, less involvement with flashbacks and a significant decrease of anxiety.   Not shown
  [@B28].                             Healthy humans/Pavlovian fear-conditioning paradigm   CBD 32 mg inhaled                                                 Enhanced consolidation of explicit fear extinction                                                            Not shown
  [@B43].                             80 patients with PTSD                                 CBD + THC (cannabis -- unknown proportion)/smoked                 Cannabis (CBD + THC) is associated with PTSD symptom reduction.                                               Not shown
  [@B90].                             10 year-old girl with PTSD (case report)              CBD oil at least 25 mg daily for 5 months/oral capsules           Maintained decrease in anxiety and a steady improvement in the quality and quantity of the patient's sleep.   Not shown
                                                                                                                                                                                                                                                                            

CBD, cannabidiol; THC, tetrahydrocannabinol.

In a study published by [@B28], CBD increased the consolidation of aversive memory extinction in healthy humans. Using inhaled CBD (at a dose of 32 mg), a study in a model of aversive conditioning showed that the compound caused a reduction in the skin conductance response as well as in the expectation levels for the CS during new exposure. Consistent with results of animal studies, these findings show that CBD may be a pharmacological complement to be used in exposure-based therapy. An important consideration in relation to this study is that CBD facilitated the extinction of aversive conditioning only when administered immediately after, and not before, the process. Therefore, understanding at which moment exposure-based therapy with CBD should start is one of several issues that still need to be resolved ([@B28]).

A case report published in 2016 by Shannon and Opila-Lehman described a 10-year-old child who developed PTSD after being sexually abused before the age of five. The child showed significant relief of the symptomatology using CBD oil. Before the CBD therapy, the child underwent standard pharmacological treatment for the condition, which produced short-lasting partial relief, as well as significant side effects. However, CBD oil (given at a dose of 12--25 mg once a day) appeared to relieve key symptoms, such as anxiety and sleep disturbance, while inducing minimal side effects. Although CBD is considered safe ([@B5]), the long-term effects were not evaluated in this study and need to be better elucidated ([@B90]).

In two other studies conducted in patients diagnosed with PTSD ([@B79]; [@B43]), chronic use of *Cannabis* significantly decreased the symptoms. However, it is not possible to analyze the proportion of CBD and THC in the plant used by the patients in these studies. Patients with PTSD may use *Cannabis* as a form of self-medication ([@B47]) in an attempt to reduce their symptoms through the anxiolytic and sedative effects ([@B13]; [@B12]), and also to induce sleep ([@B89]). Recent studies also point to a link between *Cannabis* use, possibly as a form of self-medication, and the occurrence of trauma-related events both in adolescents ([@B15]) and adults ([@B26]). The more severe the traumatic experience, the greater the plant consumption ([@B53]). These findings may reinforce the theory that the entourage effect may be more important to the therapeutic effects of the plant than any single compound used in isolation. To confirm this theory, more studies are required (for a review of *Cannabis* use in people with traumatic experiences, see [@B105]).

Multiple Mechanisms of CBD Action: How Does It Work, Anyway?
============================================================

The mechanisms of CBD action in behavioral responses related to trauma are still unclear. Understanding the mechanisms underlying CBD action, for example on the expression of aversive memories, is important because a better understanding of this phenomenon may lead to the possibility of more effective interventions in traumatic memories in PTSD. Several mechanisms of action have been proposed to explain the pharmacology of CBD and, as we shall see, they are far from universally accepted.

Within the eCB system, CBD weakly binds to CB1 and CB2 receptors ([@B81]), and some evidence suggests that it may inhibit both the uptake and hydrolysis (by FAAH) of AEA, an eCB ligand. Thus, CBD may activate CB1 receptors indirectly, by potentiating the eCB system ([@B8]; [@B32]; [@B59]; [@B36]). Based on this assumption and taking into account different studies showing that the activation of CB1 receptors decreases the expression of behaviors related to aversive memories in rats ([@B24]; [@B78], [@B77]; [@B9]), the action of CBD on such memories may be attributable to indirect potentiation of the eCB system.

A recent review by [@B47] proposed that a state of eCB deficiency might represent a stress endophenotype predisposing the individual to the development of trauma-related psychopathology. This work lends further credence to the possibility of CBD enhancing eCB signaling as a possible explanation for the therapeutic effects of CBD and, consequently, its potential to treat PTSD. Furthermore, animal studies have confirmed the importance of the CB1 receptor in mediating the effects of CBD on behavioral responses related to potentially traumatic memories ([@B9]; [@B96], [@B97]; [@B34]; [@B40]).

However, other research has shown that the answer will not be that simple. In a systematic search of the extant literature for original articles on the molecular pharmacology of CBD, we found a study by [@B50], which suggested that CBD was unlikely to exert its effects in neurological diseases through modulation of the eCB system. The authors show that CBD can act through 65 discrete, specific molecular targets, including 10 receptors, 32 enzymes, 10 ion channels, and 13 transporters. With regard to the possible modulation of the eCB system, a study published by [@B68] showed that CBD stimulated (rather than inhibited, as previously proposed) FAAH, which is involved in the catabolism of AEA; reports of CBD effects on this target are conflicting in the literature. In addition, inhibition of FAAH by CBD *in vitro* is only manifested at high concentrations, which may be difficult to achieve *in vivo*, given the relatively poor bioavailability of CBD ([@B50]). Nevertheless, because FAAH activity appears to be increased by chronic restraint stress in animal models as well as by anxiety-like behaviors ([@B48]), FAAH inhibition by CBD appears to us as a possible alternative to explain the CBD effects in aversive memories. In any case, a great deal of caution is needed when interpreting *in vitro* assays and, especially, when extrapolating *in vitro* results to the *in vivo* effects of CBD. Taking into account a possible inhibitory effect of high doses of CBD on the FAAH transporter, it appears likely that incomplete inhibition of FAAH by CBD underlies at least some of its effects *in vivo* ([@B8]; [@B32]). This mechanism may be the most promising possibility to explain at a molecular level the inhibitory effects of CBD on behavioral responses related to the recall of traumatic events and it is worth further investigation.

While reports of CBD effects on the eCB system have been contradictory, another molecular target that appears consistent with some of the stress-attenuating effects of CBD may involve serotoninergic transmission via 5-HT receptors ([@B18]; [@B16]; [@B41]). Seven different types of serotoninergic receptors have been identified (5-HT~1-7~), and the 5-HT~1~ class is further subdivided into five other subclasses (5-HT~1A,B,D,E,andF~). Of the latter, 5-HT~1A~ is the main receptor related to CBD effects, with CBD facilitating 5HT~1A~-mediated neurotransmission by acting as an agonist ([@B88]), promoting anxiolytic effects ([@B18]; [@B42]; [@B19]), mitigating stress responses ([@B84]), and, most importantly, reducing the expression of contextual fear conditioning ([@B41]). However, controversy regarding the effects of CBD on serotonergic transmission remains. A study by [@B86] showed that CBD was not a 5HT~1A~ receptor agonist as originally proposed. In this study, the authors suggested that the 5HT~1A~-mediated effects of CBD might involve allosteric interactions with the receptor binding site or interference with intracellular pathways ([@B86]). The possible interaction of CBD with the serotonergic receptor, also observed in the eCB system, has not been confirmed *in vivo* ([@B50]).

Another molecular target, still less explored, that may mediate, at least in part, the effects of CBD on the expression of aversive memories, is the adenosinergic system. [@B35] showed that specific pharmacological or genetic blockade of the P2X7R adenosinergic receptor promoted anxiogenic-like effects, along with deficits in extinction learning. It has now been established that the blocking of the eCB system leads to an increase in the expression of fear responses, whereas eCB system stimulation causes a decrease in such responses. Drawing parallels between eCB and adenosinergic signaling, adenosinergic receptor stimulation (direct or indirect) may represent an alternative treatment for trauma-related psychiatric disorders. Moreover, indirect stimulation of the adenosinergic system may explain the effects of CBD on aversive memories. [@B21] showed, also *in vitro*, that CBD decreased the uptake of adenosine and, therefore, might increase endogenous adenosine signaling. Given the precariousness of the extrapolation of *in vitro* results to *in vivo* effects, the potential role of the adenosinergic system in the CBD-induced inhibition of aversive memory expression requires further investigation.

We are still far from reaching a consensus regarding the possibility of other molecular targets mediating the effects of CBD on aversive memories. Precisely for this reason, great care must be taken when interpreting the existing literature as well as proposing new experiments. For a detailed review of the pharmacological mechanisms underlying CBD action, see [@B69], [@B17], [@B56], and especially [@B50], who reviewed dozens of potential molecular targets of CBD, questioning its action on the eCB system.

In addition to the behavioral changes induced by treatment with CBD, some of which possibly mediated by the CB1 receptor, studies have also shown that chronic CBD treatment may facilitate neurogenesis in the hippocampus, a structure well known for its important role in processing memories ([@B102]; [@B20]), and that is found reduced in patients with PTSD ([@B92]). Among the brain areas implicated in the effects of CBD, it is also important to highlight the amygdala, which is hyperactive in patients with PTSD and may be related to the severity of the symptoms ([@B92]; [@B80]; [@B37]). CBD attenuated the level of blood oxygenation in the amygdalae of healthy subjects exposed to different levels of anxiety ([@B38]), and decreased c-fos protein expression in the mouse amygdala ([@B98]). Reduction in the hyperactivity of the amygdala may also explain, in part, the therapeutic effects of CBD against the symptoms caused by PTSD ([@B79]). The activity of the mPFC, a brain structure that plays an important role in the effects of CBD on the regulation of aversive responses ([@B57]; [@B34]), is also reduced in patients with PTSD ([@B54]).

Finally, CBD-induced reduction of trauma-related responses raises a wide spectrum of possibilities involving multiple pharmacological and neural circuit mechanisms. Understanding how these mechanisms work is just one more of the various challenges in the study of cannabinoids as potential treatment for neuropsychiatric disorders.

Conclusion and Future Perspectives
==================================

Human and animal studies suggest that CBD may offer therapeutic benefits for disorders related to inappropriate responses to traumatic memories. The effects of CBD on the different stages of aversive memory processing make this compound a candidate pharmacological adjunct to psychological therapies for PTSD. CBD also shows an action profile with fewer side effects than the pharmacological therapy currently used to treat this type of disorder. In addition, even at high doses, CBD does not show the anxiogenic profile of compounds that directly activate eCB transmission.

However, even in the face of evidence pointing to the modulation of the eCB system, more studies are needed to develop a better understanding of the neurobiological mechanisms involved in CBD responses. Additional controlled studies showing the efficacy of CBD for PTSD in humans are also needed. Although much remains to be discovered about the effects of CBD on PTSD symptoms many steps have already been taken in this direction, which may yield a formulation of CBD for the treatment of patients with trauma and stress-related disorders.
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